It is our pleasure to share with you our Outlook on ‘Specialized Chemistry Outsourcing’

Complex modalities like ADCs, OligonucleoTIDES, PepTIDES (TIDES), etc. are becoming a key part of the biopharma pipeline, with applications across a wide range of indications. However, the infancy of ADC and the TIDES therapeutics pose several development and manufacturing challenges, from technology and process development to manufacturing and fill-finish. Therefore, biopharma is turning to outsourcing partners to offer strategic support to address these challenges.

CDMOs, in turn, are building proprietary technology platforms and manufacturing capabilities through a range of strategic initiatives, both organic and inorganic, to position themselves as preferred partners.

You can download the presentation here.